FBInvestor
Funds / Sands Capital Alternatives, LLC
Institutional Fund

Sands Capital Alternatives, LLC

Arlington, VACIK 18464445 filings on record

Portfolio Value
$421.20M
Q1 2026
Holdings
21
Reported positions
New Buys
1
Opened this quarter
QoQ Change
-18.8%
from $518.47M

Portfolio Value Trend

Reported 13F value by quarter

Portfolio value trend — upgrade to see history

Upgrade

Top Allocations

Largest positions by weight

  • Nu Hldgs Ltd22.3%
  • Klaviyo Inc16.9%
  • Spyglass Pharma Inc15.4%
  • Beta Bionics Inc8.8%
  • Inhibikase Therapeutics Inc5.2%
  • Coupang Inc4.5%
  • Other26.9%

Portfolio Holdings

21 positions · Q1 2026

#SecuritySharesValue% Port.Δ SharesActivity
1Nu Hldgs Ltd6.54M$93.95M22.3%323.6KReduced
2Klaviyo Inc3.65M$71.02M16.9%0Held
3Spyglass Pharma Inc2.50M$64.78M15.4%+2.50MNew
4Beta Bionics Inc3.71M$37.15M8.8%+137.9KAdded
5Inhibikase Therapeutics Inc13.02M$21.87M5.2%0Held
6Coupang Inc1.01M$19.11M4.5%+141.7KAdded
7Samsara Inc560.3K$17.76M4.2%+94.1KAdded
8Doordash Inc111.2K$16.70M4.0%+15.6KAdded
9Bioage Labs Inc786.4K$13.75M3.3%0Held
1010x Genomics Inc481.8K$10.23M2.4%0Held

11 more holdings on Premium

See this fund's complete portfolio, full position changes, and activity history.

Unlock full portfolio